{
  "case_id": "case_0020",
  "provider": "openai",
  "status": "processed",
  "patient_demographics": {
    "age": 38.15,
    "sex": "Male",
    "genderIdentity": "Transgender Male",
    "ancestry": "Sub-Saharan African"
  },
  "marking_output": {
    "Localisation": {
      "report_string": "--- Localisation ---\nAgree with lesion involving:\n- right optic nerve (cranial nerve II).",
      "structured_data": {
        "gt_lesions_english": [
          "right optic nerve (cranial nerve II)"
        ],
        "ft_lesions_parsed": [
          {
            "location": "optic nerve",
            "side": "right",
            "qualifier": null
          }
        ],
        "exact_matches": [
          "right optic nerve (cranial nerve II)"
        ],
        "imprecise_matches": [],
        "missing_lesions_from_ft": [],
        "additional_lesions_in_ft": []
      },
      "scoring": {
        "gt_lesion_count": 1,
        "correctly_identified_count": 1,
        "imprecisely_identified_count": 0,
        "missed_lesion_count": 0,
        "additional_lesion_count": 0,
        "proportion_correct": 1.0,
        "proportion_imprecise": 0.0,
        "proportion_missed": 0.0,
        "proportion_additional": 0.0
      }
    },
    "Differential diagnosis": {
      "report_string": "--- Differential diagnosis ---\nCorrectly included: Multiple sclerosis\n  \nThese suggested differentials are reasonable:\n\n- MOG antibody\u2013associated disease (optic neuritis); Aquaporin-4 IgG neuromyelitis optica spectrum disorder (optic neuritis); Non-arteritic anterior ischemic optic neuropathy; Compressive optic neuropathy (e.g., optic nerve sheath meningioma); Leber hereditary optic neuropathy; Optic neuropathy due to sarcoidosis/syphilis/Lyme",
      "structured_data": {
        "ft_diagnoses_raw": [
          "Demyelinating optic neuritis (multiple sclerosis\u2013associated)",
          "MOG antibody\u2013associated disease (optic neuritis)",
          "Aquaporin-4 IgG neuromyelitis optica spectrum disorder (optic neuritis)",
          "Non-arteritic anterior ischemic optic neuropathy",
          "Compressive optic neuropathy (e.g., optic nerve sheath meningioma)",
          "Leber hereditary optic neuropathy",
          "Optic neuropathy due to sarcoidosis/syphilis/Lyme"
        ],
        "gt_diagnoses_with_source": {
          "Multiple sclerosis": "evaluation",
          "Thrombophilia": "comorbidity"
        },
        "correctly_mentioned": [
          "Multiple sclerosis"
        ],
        "missing_diagnoses": [
          "Thrombophilia"
        ],
        "additional_diagnoses": [
          "MOG antibody\u2013associated disease (optic neuritis)",
          "Aquaporin-4 IgG neuromyelitis optica spectrum disorder (optic neuritis)",
          "Non-arteritic anterior ischemic optic neuropathy",
          "Compressive optic neuropathy (e.g., optic nerve sheath meningioma)",
          "Leber hereditary optic neuropathy",
          "Optic neuropathy due to sarcoidosis/syphilis/Lyme"
        ]
      },
      "scoring": {
        "ms_included": 1,
        "incidental_total_count": 0,
        "incidental_missing_count": 0,
        "incidental_missing_proportion": null,
        "comorbidity_total_count": 0,
        "comorbidity_missing_count": 0,
        "comorbidity_missing_proportion": null
      }
    },
    "Investigations": {
      "report_string": "--- Investigations ---\nAgree with all suggestions.\n\n- MRI including the Orbits and CSF test for Oligoclonal Bands would potentially inform a diagnosis of multiple sclerosis.",
      "structured_data": {
        "gt_required_tests": [
          {
            "type": "CSF",
            "detail": "Oligoclonal Bands",
            "condition": "Multiple sclerosis"
          },
          {
            "type": "MRI",
            "region": "Orbits",
            "condition": "Multiple sclerosis"
          }
        ],
        "ft_proposed_investigations": [
          "MRI brain and orbits with gadolinium (fat-suppressed sequences)",
          "MRI cervical and thoracic spine with gadolinium",
          "Humphrey automated visual fields",
          "Optical coherence tomography (RNFL and macula)",
          "Dilated fundus examination (ophthalmology)",
          "Visual evoked potentials",
          "Full blood count",
          "Urea and electrolytes",
          "Liver function tests",
          "C-reactive protein",
          "Erythrocyte sedimentation rate",
          "Blood glucose",
          "Vitamin B12 level",
          "Serum angiotensin-converting enzyme",
          "Aquaporin-4 IgG (cell-based assay)",
          "MOG-IgG (cell-based assay)",
          "Syphilis serology (treponemal and non-treponemal)",
          "Lyme disease serology",
          "HIV antigen/antibody test",
          "Antinuclear antibody",
          "Extractable nuclear antigen panel",
          "Chest X-ray",
          "Lumbar puncture with CSF cell count, protein, glucose, and oligoclonal bands"
        ],
        "found_tests": [
          {
            "type": "CSF",
            "detail": "Oligoclonal Bands",
            "condition": "Multiple sclerosis"
          },
          {
            "type": "MRI",
            "region": "Orbits",
            "condition": "Multiple sclerosis"
          }
        ],
        "missing_tests": []
      },
      "scoring": {
        "gt_tests_count": 2,
        "found_tests_count": 2,
        "missing_tests_count": 0,
        "proportion_found": 1.0,
        "proportion_missing": 0.0
      }
    },
    "Management": {
      "report_string": "--- Management ---\nSteroids: Unsafe decision to start treatment now.\n  \nAdditional factors not mentioned:\n\n- Symptoms started more than 14 days\n\n- Safety screen for contraindications like active infection is required before immunosuppression.\n\nDMTs: Appropriate decision to consider but delay treatment.\n  \nCorrectly identified the following:\n\n- Need confirmation of MS diagnosis.\n  \nAdditional factors not mentioned:\n\n- Safety screen for contraindications like active infection is required before immunosuppression.",
      "structured_data": {
        "ft_full_plan_parsed": [
          {
            "treatment": "Intravenous methylprednisolone 1 g daily for 3\u20135 days",
            "timing": "Start Now",
            "reasons": [
              "Typical unilateral optic neuritis with reduced acuity and RAPD",
              "Speeds visual recovery",
              "First-line for demyelinating, MOGAD, and NMOSD optic neuritis"
            ]
          },
          {
            "treatment": "Oral prednisolone taper (e.g., 0.5\u20131 mg/kg for 1\u20132 weeks) after IV course",
            "timing": "Start Now",
            "reasons": [
              "Prevents rebound after IV steroids",
              "Standard adjunct following IV methylprednisolone in optic neuritis"
            ]
          },
          {
            "treatment": "Gastroprotection and metabolic monitoring during steroids (PPI, glucose checks, BP monitoring)",
            "timing": "Start Now",
            "reasons": [
              "Mitigate steroid adverse effects",
              "Patient safety while on high-dose steroids"
            ]
          },
          {
            "treatment": "Plasma exchange (5\u20137 exchanges)",
            "timing": "Delay",
            "reasons": [
              "Reserve if poor visual recovery within 1\u20132 weeks",
              "Indicated for severe NMOSD/MOGAD relapses unresponsive to steroids"
            ]
          },
          {
            "treatment": "Disease-modifying therapy for multiple sclerosis (agent per MRI/CSF and risk profile)",
            "timing": "Delay",
            "reasons": [
              "Initiate only if MS diagnosis established",
              "Prevents future relapses and disability"
            ]
          },
          {
            "treatment": "Rituximab-based maintenance immunotherapy",
            "timing": "Delay",
            "reasons": [
              "Start if AQP4-IgG NMOSD confirmed",
              "Reduces relapse risk"
            ]
          },
          {
            "treatment": "IVIG or steroid-sparing immunotherapy (e.g., mycophenolate/azathioprine) for MOGAD",
            "timing": "Delay",
            "reasons": [
              "Consider if MOG-IgG positive or relapsing course",
              "Prevents further optic neuritis attacks"
            ]
          },
          {
            "treatment": "Antiplatelet therapy (aspirin) or anticoagulation only if ischemic optic neuropathy/vascular aetiology confirmed",
            "timing": "Delay",
            "reasons": [
              "Not indicated without vascular diagnosis",
              "Avoids unnecessary bleeding risk despite thrombophilia history"
            ]
          }
        ],
        "steroids_evaluation": {
          "ft_plan": {
            "treatment": "Intravenous methylprednisolone 1 g daily for 3\u20135 days",
            "timing": "Start Now",
            "reasons": [
              "Typical unilateral optic neuritis with reduced acuity and RAPD",
              "Speeds visual recovery",
              "First-line for demyelinating, MOGAD, and NMOSD optic neuritis"
            ]
          },
          "gt_plan": {
            "treatment_inappropriate": true,
            "reasons": {
              "missing_information": [
                "Safety screen for contraindications like active infection is required before immunosuppression."
              ],
              "contraindications": [
                "Symptoms started more than 14 days"
              ]
            }
          },
          "evaluation_summary": "Unsafe decision to start treatment now.\n  \nAdditional factors not mentioned:\n\n- Symptoms started more than 14 days\n\n- Safety screen for contraindications like active infection is required before immunosuppression."
        },
        "dmt_evaluation": {
          "ft_plan": {
            "treatment": "Disease-modifying therapy for multiple sclerosis (agent per MRI/CSF and risk profile)",
            "timing": "Delay",
            "reasons": [
              "Initiate only if MS diagnosis established",
              "Prevents future relapses and disability"
            ]
          },
          "gt_plan": {
            "treatment_inappropriate": true,
            "reasons": {
              "missing_information": [
                "Need confirmation of MS diagnosis.",
                "Safety screen for contraindications like active infection is required before immunosuppression."
              ],
              "contraindications": []
            }
          },
          "evaluation_summary": "Appropriate decision to consider but delay treatment.\n  \nCorrectly identified the following:\n\n- Need confirmation of MS diagnosis.\n  \nAdditional factors not mentioned:\n\n- Safety screen for contraindications like active infection is required before immunosuppression."
        }
      },
      "scoring": {
        "steroids": {
          "decision_safety": 1,
          "gt_reasons_count": 2,
          "acknowledged_reasons_count": 0,
          "missed_reasons_count": 2,
          "proportion_reasons_acknowledged": 0.0,
          "proportion_reasons_missed": 1.0
        },
        "dmt": {
          "decision_safety": 0,
          "gt_reasons_count": 2,
          "acknowledged_reasons_count": 1,
          "missed_reasons_count": 1,
          "proportion_reasons_acknowledged": 0.5,
          "proportion_reasons_missed": 0.5
        }
      }
    }
  }
}